APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short Bowel Syndrome (SBS) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Short Bowel Syndrome (SBS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025189 pages

Choose your research edition.

Industry ResearchShort Bowel Syndrome (SBS) Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Short Bowel Syndrome (SBS) Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Short Bowel Syndrome (SBS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short Bowel Syndrome (SBS) Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Short Bowel Syndrome (SBS) Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Short Bowel Syndrome (SBS) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Short Bowel Syndrome (SBS) Drugs include Takeda, Merck, Zealand Pharma, Sancilio Pharmaceuticals, OxThera, Nutrinia, Naia Pharmaceuticals, Emmaus Medical and Ardelyx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Short Bowel Syndrome (SBS) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Short Bowel Syndrome (SBS) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Short Bowel Syndrome (SBS) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Short Bowel Syndrome (SBS) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Short Bowel Syndrome (SBS) Drugs Segment by Company

Takeda

Merck

Zealand Pharma

Sancilio Pharmaceuticals

OxThera

Nutrinia

Naia Pharmaceuticals

Emmaus Medical

Ardelyx

Short Bowel Syndrome (SBS) Drugs Segment by Type

Glutamine

Growth Hormone

Glucagon-Like Peptide-2 (GLP-2)

Other

Short Bowel Syndrome (SBS) Drugs Segment by Application

Hospitals

Clinics

Retail Pharmacies

Short Bowel Syndrome (SBS) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short Bowel Syndrome (SBS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short Bowel Syndrome (SBS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short Bowel Syndrome (SBS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Short Bowel Syndrome (SBS) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Short Bowel Syndrome (SBS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Short Bowel Syndrome (SBS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Short Bowel Syndrome (SBS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Short Bowel Syndrome (SBS) Drugs Industry Trends Table 2. Short Bowel Syndrome (SBS) Drugs Industry Drivers Table 3. Short Bowel Syndrome (SBS) Drugs Industry Opportunities and Challenges Table 4. Short Bowel Syndrome (SBS) Drugs Industry Restraints Table 5. Global Short Bowel Syndrome (SBS) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Short Bowel Syndrome (SBS) Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Manufacturers Table 9. Global Short Bowel Syndrome (SBS) Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Short Bowel Syndrome (SBS) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Short Bowel Syndrome (SBS) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Short Bowel Syndrome (SBS) Drugs Manufacturers, Product Type & Application Table 13. Global Short Bowel Syndrome (SBS) Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Short Bowel Syndrome (SBS) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Glutamine Table 17. Major Manufacturers of Growth Hormone Table 18. Major Manufacturers of Glucagon-Like Peptide-2 (GLP-2) Table 19. Major Manufacturers of Other Table 20. Global Short Bowel Syndrome (SBS) Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021-2026) & (K Units) Table 22. Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2027-2032) & (K Units) Table 23. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Type (2021-2026) Table 24. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Type (2027-2032) Table 25. Global Short Bowel Syndrome (SBS) Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Short Bowel Syndrome (SBS) Drugs Revenue by Type (2021-2026) & (K Units) Table 27. Global Short Bowel Syndrome (SBS) Drugs Revenue by Type (2027-2032) & (K Units) Table 28. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Clinics Table 32. Major Manufacturers of Retail Pharmacies Table 33. Global Short Bowel Syndrome (SBS) Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Application (2021-2026) Table 37. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Application (2027-2032) Table 38. Global Short Bowel Syndrome (SBS) Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Short Bowel Syndrome (SBS) Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global Short Bowel Syndrome (SBS) Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Region (2021-2026) Table 46. Global Short Bowel Syndrome (SBS) Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Short Bowel Syndrome (SBS) Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America Short Bowel Syndrome (SBS) Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe Short Bowel Syndrome (SBS) Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Short Bowel Syndrome (SBS) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Short Bowel Syndrome (SBS) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Short Bowel Syndrome (SBS) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Region (2027-2032) Table 65. Takeda Company Information Table 66. Takeda Business Overview Table 67. Takeda Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Takeda Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 69. Takeda Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 74. Merck Recent Development Table 75. Zealand Pharma Company Information Table 76. Zealand Pharma Business Overview Table 77. Zealand Pharma Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Zealand Pharma Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 79. Zealand Pharma Recent Development Table 80. Sancilio Pharmaceuticals Company Information Table 81. Sancilio Pharmaceuticals Business Overview Table 82. Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 84. Sancilio Pharmaceuticals Recent Development Table 85. OxThera Company Information Table 86. OxThera Business Overview Table 87. OxThera Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. OxThera Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 89. OxThera Recent Development Table 90. Nutrinia Company Information Table 91. Nutrinia Business Overview Table 92. Nutrinia Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Nutrinia Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 94. Nutrinia Recent Development Table 95. Naia Pharmaceuticals Company Information Table 96. Naia Pharmaceuticals Business Overview Table 97. Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 99. Naia Pharmaceuticals Recent Development Table 100. Emmaus Medical Company Information Table 101. Emmaus Medical Business Overview Table 102. Emmaus Medical Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Emmaus Medical Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 104. Emmaus Medical Recent Development Table 105. Ardelyx Company Information Table 106. Ardelyx Business Overview Table 107. Ardelyx Short Bowel Syndrome (SBS) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Ardelyx Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 109. Ardelyx Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Short Bowel Syndrome (SBS) Drugs Distributors List Table 113. Short Bowel Syndrome (SBS) Drugs Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Short Bowel Syndrome (SBS) Drugs Product Image Figure 2. Global Short Bowel Syndrome (SBS) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Short Bowel Syndrome (SBS) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Short Bowel Syndrome (SBS) Drugs Sales (2021-2032) & (K Units) Figure 5. Global Short Bowel Syndrome (SBS) Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Short Bowel Syndrome (SBS) Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Glutamine Image Figure 9. Growth Hormone Image Figure 10. Glucagon-Like Peptide-2 (GLP-2) Image Figure 11. Other Image Figure 12. Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Short Bowel Syndrome (SBS) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Retail Pharmacies Image Figure 21. Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Short Bowel Syndrome (SBS) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Short Bowel Syndrome (SBS) Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Short Bowel Syndrome (SBS) Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales Market Share by Country (2021-2032) Figure 41. China Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Short Bowel Syndrome (SBS) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Short Bowel Syndrome (SBS) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Short Bowel Syndrome (SBS) Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Short Bowel Syndrome (SBS) Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Glutamine
  • Growth Hormone
  • Glucagon-Like Peptide-2 (GLP-2)
  • Other
Applications
  • Hospitals
  • Clinics
  • Retail Pharmacies
Companies covered
  • Takeda
  • Merck
  • Zealand Pharma
  • Sancilio Pharmaceuticals
  • OxThera
  • Nutrinia
  • Naia Pharmaceuticals
  • Emmaus Medical
  • Ardelyx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Short Bowel Syndrome (SBS) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Short Bowel Syndrome (SBS) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Short Bowel Syndrome (SBS) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Short Bowel Syndrome (SBS) Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Short Bowel Syndrome (SBS) Drugs Market Dynamics
  1. 2.1 Short Bowel Syndrome (SBS) Drugs Industry Trends
  2. 2.2 Short Bowel Syndrome (SBS) Drugs Industry Drivers
  3. 2.3 Short Bowel Syndrome (SBS) Drugs Industry Opportunities and Challenges
  4. 2.4 Short Bowel Syndrome (SBS) Drugs Industry Restraints
3 Short Bowel Syndrome (SBS) Drugs Market by Manufacturers
  1. 3.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Short Bowel Syndrome (SBS) Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Short Bowel Syndrome (SBS) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Short Bowel Syndrome (SBS) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Short Bowel Syndrome (SBS) Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Short Bowel Syndrome (SBS) Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Short Bowel Syndrome (SBS) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Short Bowel Syndrome (SBS) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Short Bowel Syndrome (SBS) Drugs Tier 1, Tier 2, and Tier 3
4 Short Bowel Syndrome (SBS) Drugs Market by Type
  1. 4.1 Short Bowel Syndrome (SBS) Drugs Type Introduction
  2. 4.1.1 Glutamine
  3. 4.1.2 Growth Hormone
  4. 4.1.3 Glucagon-Like Peptide-2 (GLP-2)
  5. 4.1.4 Other
  6. 4.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Type
  7. 4.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Short Bowel Syndrome (SBS) Drugs Revenue by Type
  11. 4.3.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Type (2021-2032)
5 Short Bowel Syndrome (SBS) Drugs Market by Application
  1. 5.1 Short Bowel Syndrome (SBS) Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Application
  6. 5.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Short Bowel Syndrome (SBS) Drugs Revenue by Application
  10. 5.3.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Application (2021-2032)
6 Global Short Bowel Syndrome (SBS) Drugs Sales by Region
  1. 6.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region
  1. 7.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region
  2. 7.1.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032)
  8. 7.2.2 North America Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Short Bowel Syndrome (SBS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Short Bowel Syndrome (SBS) Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Short Bowel Syndrome (SBS) Drugs Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Zealand Pharma
  14. 8.3.1 Zealand Pharma Company Information
  15. 8.3.2 Zealand Pharma Business Overview
  16. 8.3.3 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Product Portfolio
  18. 8.3.5 Zealand Pharma Recent Developments
  19. 8.4 Sancilio Pharmaceuticals
  20. 8.4.1 Sancilio Pharmaceuticals Company Information
  21. 8.4.2 Sancilio Pharmaceuticals Business Overview
  22. 8.4.3 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio
  24. 8.4.5 Sancilio Pharmaceuticals Recent Developments
  25. 8.5 OxThera
  26. 8.5.1 OxThera Company Information
  27. 8.5.2 OxThera Business Overview
  28. 8.5.3 OxThera Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 OxThera Short Bowel Syndrome (SBS) Drugs Product Portfolio
  30. 8.5.5 OxThera Recent Developments
  31. 8.6 Nutrinia
  32. 8.6.1 Nutrinia Company Information
  33. 8.6.2 Nutrinia Business Overview
  34. 8.6.3 Nutrinia Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Nutrinia Short Bowel Syndrome (SBS) Drugs Product Portfolio
  36. 8.6.5 Nutrinia Recent Developments
  37. 8.7 Naia Pharmaceuticals
  38. 8.7.1 Naia Pharmaceuticals Company Information
  39. 8.7.2 Naia Pharmaceuticals Business Overview
  40. 8.7.3 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio
  42. 8.7.5 Naia Pharmaceuticals Recent Developments
  43. 8.8 Emmaus Medical
  44. 8.8.1 Emmaus Medical Company Information
  45. 8.8.2 Emmaus Medical Business Overview
  46. 8.8.3 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Product Portfolio
  48. 8.8.5 Emmaus Medical Recent Developments
  49. 8.9 Ardelyx
  50. 8.9.1 Ardelyx Company Information
  51. 8.9.2 Ardelyx Business Overview
  52. 8.9.3 Ardelyx Short Bowel Syndrome (SBS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ardelyx Short Bowel Syndrome (SBS) Drugs Product Portfolio
  54. 8.9.5 Ardelyx Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Short Bowel Syndrome (SBS) Drugs Value Chain Analysis
  2. 9.1.1 Short Bowel Syndrome (SBS) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Short Bowel Syndrome (SBS) Drugs Production Mode & Process
  6. 9.2 Short Bowel Syndrome (SBS) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Short Bowel Syndrome (SBS) Drugs Distributors
  9. 9.2.3 Short Bowel Syndrome (SBS) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst